AU2001274817A1 - Agents that modulate dna-pk activity and methods of use thereof - Google Patents
Agents that modulate dna-pk activity and methods of use thereofInfo
- Publication number
- AU2001274817A1 AU2001274817A1 AU2001274817A AU7481701A AU2001274817A1 AU 2001274817 A1 AU2001274817 A1 AU 2001274817A1 AU 2001274817 A AU2001274817 A AU 2001274817A AU 7481701 A AU7481701 A AU 7481701A AU 2001274817 A1 AU2001274817 A1 AU 2001274817A1
- Authority
- AU
- Australia
- Prior art keywords
- agents
- activity
- methods
- modulate dna
- modulate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20227400P | 2000-05-05 | 2000-05-05 | |
US60202274 | 2000-05-05 | ||
US26232101P | 2001-01-17 | 2001-01-17 | |
US60262321 | 2001-01-17 | ||
PCT/US2001/014508 WO2001085910A2 (en) | 2000-05-05 | 2001-05-04 | Agents that modulate dna-pk activity and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001274817A1 true AU2001274817A1 (en) | 2001-11-20 |
Family
ID=26897522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001274817A Abandoned AU2001274817A1 (en) | 2000-05-05 | 2001-05-04 | Agents that modulate dna-pk activity and methods of use thereof |
Country Status (3)
Country | Link |
---|---|
US (2) | US6893821B2 (en) |
AU (1) | AU2001274817A1 (en) |
WO (1) | WO2001085910A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
WO2001095935A1 (en) * | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
US7354909B2 (en) * | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
WO2004021243A2 (en) * | 2002-08-09 | 2004-03-11 | Siemens Aktiengesellschaft | Method and computer program comprising program code means, and computer program product for analysing the activity of a pharmaceutical preparation |
US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
EP1578954A4 (en) | 2002-12-11 | 2010-08-11 | Coley Pharm Group Inc | 5' cpg nucleic acids and methods of use |
US20050084890A1 (en) * | 2003-10-07 | 2005-04-21 | Turchi John J. | High-throughput screening assay for inhibitors of replication protein A |
US20060110390A1 (en) * | 2004-08-25 | 2006-05-25 | Myogen, Inc. | Inhibition of Ku as a treatment for cardiovascular diseases |
CN101171033A (en) * | 2005-03-04 | 2008-04-30 | 戴纳瓦克斯技术公司 | Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients |
EP1904530A2 (en) * | 2005-07-07 | 2008-04-02 | Coley Pharmaceutical Group, Inc. | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
WO2007030581A2 (en) * | 2005-09-09 | 2007-03-15 | Oregon Health & Science University | Neuroprotectants |
US20100130425A1 (en) * | 2005-09-09 | 2010-05-27 | Oregon Health & Science University | Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia |
US20210008161A1 (en) | 2019-06-17 | 2021-01-14 | Crispr Therapeutics Ag | Methods and compositions for improved homology directed repair |
US20230095192A1 (en) * | 2020-03-03 | 2023-03-30 | University Of Washington | Synthetic agonists of dna-pk and their use |
AU2021400745A1 (en) | 2020-12-17 | 2023-07-20 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1872786A1 (en) * | 1997-09-05 | 2008-01-02 | The Regents of the University of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
US6441158B1 (en) * | 1997-12-31 | 2002-08-27 | Medical College Of Georgia Research Institute, Inc. | Oligomers that bind to ku protein |
DE60013591T2 (en) | 1999-04-29 | 2005-02-03 | Coley Pharmaceutical Gmbh | SCREENING FOR MODULATORS OF THE FUNCTION OF IMMUNSTIMULATORY DNA |
-
2001
- 2001-05-04 WO PCT/US2001/014508 patent/WO2001085910A2/en active Application Filing
- 2001-05-04 US US09/848,986 patent/US6893821B2/en not_active Expired - Fee Related
- 2001-05-04 AU AU2001274817A patent/AU2001274817A1/en not_active Abandoned
-
2002
- 2002-08-30 US US10/233,121 patent/US20030125284A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030125284A1 (en) | 2003-07-03 |
WO2001085910A2 (en) | 2001-11-15 |
WO2001085910A3 (en) | 2002-04-04 |
US6893821B2 (en) | 2005-05-17 |
US20030176373A1 (en) | 2003-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001274817A1 (en) | Agents that modulate dna-pk activity and methods of use thereof | |
AU2002211389A1 (en) | Microfluidic devices and methods of use | |
AU4520801A (en) | Novel substituted phenanthridinones and methods of use thereof | |
AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
AU6340600A (en) | Telomerase inhibitors and methods of their use | |
AU8140898A (en) | Inhibitors of beta-lactamases and uses therefor | |
AU2002314466A1 (en) | Withasol and methods of use | |
AU3622600A (en) | Metalloproteinases and methods of use therefor | |
AU2002213346A1 (en) | Osteopontin-coated surfaces and methods of use | |
HK1031128A1 (en) | Jnk3 modulators and methods of use | |
AU2002337913A1 (en) | Glycosulfopeptide inhibitors and methods of use thereof | |
AU2002231206A1 (en) | Treatment of depression | |
AU2002230717A1 (en) | Use of convergence-enabled dvd and web system | |
AU2002233608A1 (en) | Modulation of gsk-3beta activity and its different uses | |
AU2001255696A1 (en) | Telomerase inhibitors and methods of their use | |
AU6406800A (en) | SF3 promoter and methods of use | |
AU4537600A (en) | Use of ion channel modulating agents | |
AU2001262939A1 (en) | Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states | |
AU2001261496A1 (en) | Luxo-sigma54 interactions and methods of use | |
AU2001249692A1 (en) | Phospholipid scramblases and methods of use thereof | |
EP1263935A4 (en) | Scytonemin and methods of using thereof | |
AU2001284380A1 (en) | Therapeutic and cosmetic uses of heparanases | |
AU2001296448A1 (en) | Tumor marker and methods of use | |
AU3725500A (en) | Hand-held bidet and method of use | |
AU1454199A (en) | Pdgf-mediated microvascular communication and methods of use thereof |